Anush Movsesian, whose clients include Hilary Duff and Kehlani, told The Post which five trends she’s staying away from — and her actual must-have for reliable anti-aging.

John Koch, a radio reporter, witnesses every execution in Florida to keep close tabs on what he considers one of the most ...

The diabetes medication semaglutide has recently become a trendy weight loss treatment. But like every drug, there are ...

As of February 2025, the semaglutide injection (Ozempic, Wegovy) shortage was resolved. As a result, compounded semaglutide ...

The global injection pen market is expected to grow at a rate of 7% over the next five years. Key factors fueling this growth include the rising prevalence of chronic diseases, the increasing demand ...

The U.S. Federal Reserve (Fed) pumped $29.4 billion into the banking system on Friday, sparking optimism on crypto social media. While the move aimed at easing liquidity concerns and is supportive of ...

Novartis has announced that its treatment for polymyalgia rheumatica (PMR), Cosentyx (secukinumab), achieved all primary and secondary endpoints in the phase 3 REPLENISH trial. REPLENISH is a global, ...

Polymyalgia rheumatica is the second most common inflammatory rheumatic disease in adults aged 50 years and older, typically characterized by acute pain and stiffness in the shoulders, neck, and hips.

Cosentyx, an autoimmune disease therapy that cost the healthcare industry $7.7 billion in 2024, will be offered at a 55% discount beginning in November. The drug’s manufacturer, Novartis, said Sept.

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

Novartis (NYSE:NVS) (OTCPK:NVSEF) announced Thursday that its FDA-approved anti-inflammatory agent Cosentyx failed to reach the main goal in a Phase 3 trial for adults with giant cell arteritis ((GCA) ...

Novartis said its Cosentyx drug failed to deliver a statistically significant improvement in sustained remission for adult patients with newly diagnosed or relapsing giant cell arteritis. The ...